DIAGNOSIS IN ONCOLOGY
“And What Other Medications Are You Taking?”
National Cancer Centre Singapore, Singapore
Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA
National Cancer Centre Singapore, Singapore
Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA
Patients with cancer face a loss of autonomy as they depend on health care providers to navigate the balance of effectiveness and toxicity of treatments that are often perceived as unusually harsh. Increasingly, these factors—as well as the proliferation of available information—lead patients to pursue complementary and alternative medicine (CAM), although the safety and efficacy of such approaches are rarely studied rigorously. Indeed, patients often hide their use of such modalities for fear of disapproval from their physicians, who might reject the notion of employing such unproven treatments.1,2
We present three patients with advanced hepatocellular carcinoma (HCC), a historically treatment-refractory disease that often occurs in patients with significant comorbidities. By asking the open-ended question, “And what other medications are you taking?” we identified a traditional Chinese medicine (TCM), Ling Zhi (Ganoderma lucidum), that has, at least in our experience, been associated with a few durable remissions.
A 78-year-old Chinese man with cirrhosis resulting from hepatitis B infection had been found by surveillance computed tomography (CT) scan 2 years before to have an early-enhancing liver mass with smaller satellite lesions. Exploratory laparoscopy, biopsy, and radiofrequency ablation were performed. Pathology revealed poorly differentiated HCC. After the procedure, his α-fetoprotein (AFP) level declined from 570.6 to 24.9 μg/L but then increased six-fold over the ensuing 3 months. Repeat imaging revealed a new retroperitoneal lymph node and cervical lymphadenopathy. Cytology from fine-needle aspiration of a cervical lymph node showed metastatic HCC. Because this occurred before US Food and Drug Administration approval of sorafenib for use in HCC in 2008, the patient was treated with doxorubicin as first-line chemotherapy. An initial decline in his AFP correlated with stable disease on follow-up CT scans. However, doxorubicin was discontinued after five cycles because of rising AFP and significant fatigue.
Shortly before doxorubicin was discontinued, the patient elected to start Ling Zhi, obtained through an advertisement in a local Chinese newspaper. Within 6 months, his AFP decreased to 6,827 μg/L from a peak of 13,074 μg/L; 2 months later, it decreased again to 15.2 μg/L. Figure 1A shows the full time course of AFP measurements, with doxorubicin initiated at month 14 and stopped at month 18; Ling Zhi was initiated during month 16 (asterisk). His retroperitoneal lymphadenopathy also decreased on ensuing CT scans (Fig 1B, arrows; month 16, left; month 24, right). Notably, his AFP continued to rise after Ling Zhi was started until doxorubicin was discontinued, suggesting that these two agents may have conflicting actions. His HCC remained quiescent for 2 years, with AFP approximately 20 μg/L and no radiographic evidence of progression. At that point, peritoneal carcinomatosis was noted on an interval scan, despite low AFP. Hospice care was initiated, and the patient died shortly thereafter.
A 69-year-old Chinese man with chronic hepatitis B infection had HCC confirmed by fine-needle aspiration after a CT scan showed a large multifocal contrast-enhancing lesion in the right lobe of the liver with probable portal vein thrombosis. Soon after diagnosis, he began taking Ling Zhi and another TCM product, the herbal preparation Gan Fu Le. He was referred to the University of California at San Francisco (UCSF) for consideration for a clinical trial 3 months after starting these TCM agents. A CT scan to determine protocol eligibility showed a dramatic reduction of the liver mass from 8.9 × 4 cm to 5.6 × 4.5 cm. He has now been observed at UCSF for 10 years, developing only mild renal insufficiency and hypertension. Serial magnetic resonance imaging of the abdomen showed progressive reduction in the size of his tumor over the first several years after diagnosis; the mass has since remained unchanged in size at 4.2 × 1.8 cm. CT of the tumor at time of initial diagnosis and magnetic resonance imaging of the residual lesion are shown in the left and right panels of Figure 1C (arrows); AFP was never significantly elevated. The patient continues to take his TCM and has never received any other cancer-directed therapy.
A 72-year-old woman was referred to the National Cancer Centre Singapore for evaluation of AFP level of 1,899 μg/L. CT showed no cirrhosis but revealed multiple contrast-enhancing liver lesions concerning for malignancy, with the dominant lesion measuring 11.8 × 9.3 × 12.7 cm in the right hepatic lobe (Fig 1D, left). There was no evidence of active hepatitis B or C infection. A single metastatic lesion was later detected in the L3 vertebral body. Given her poor performance status and limited therapeutic options, the patient and her family decided to pursue supportive care, declining biopsy. She sought advice from a TCM practitioner and began taking Ling Zhi and Pian Zhi Huang, a TCM preparation including gardenia, notoginseng, and Ling Zhi. After this, she remained asymptomatic, and her AFP declined to 7.2 μg/L (Fig 1A; Ling Zhi initiated during month 2 [dagger]). Repeat CT of the abdomen performed 12 months after diagnosis showed her dominant lesion had shrunk to 5.4 cm in longest diameter, and her lesions were now all hypovascular (Fig 1D, right). Since that time 9 months ago, she has had a stably low AFP level and no symptoms of disease, continuing her TCM.
The medical literature has many reports of spontaneous remission of HCC, found to occur in 0.406% of patients in a systematic review of the placebo arms of 10 clinical trials, including 1,640 patients.3 A review of many of individually published reports of spontaneous remissions revealed that these were categorized as such because there had been no conventional cancer treatment. However, these patients were often noted to have been taking herbal preparations, particularly TCM,4–6 which was thought to provide symptom palliation for HCC.7
Our case series is intriguing in the context of these reports. HCC is felt to be largely refractory to treatment.8,9 Conventional chemotherapy, in single-agent or multidrug regimens, has not shown a survival benefit for patients with advanced or metastatic disease, for whom median survival is generally shorter than 8 months.10–12 Although the multikinase inhibitor sorafenib prolongs survival in patients with early cirrhosis and preserved liver function,12,13 it infrequently leads to radiographic responses and seems significantly less beneficial to patients with advanced cirrhosis.14,15 Furthermore, phase III trials that demonstrated efficacy of sorafenib for HCC specifically excluded patients with bilirubin greater than 3 mg/dL and Child-Pugh class B or greater liver dysfunction.12,13 These criteria exclude the majority of patients with newly diagnosed HCC.16 Thus, not only are the systemic therapeutic options for HCC limited in efficacy, there remains a sizeable population of patients with HCC who are poor candidates for these therapies because of underlying liver dysfunction.17
CAM has come to play a significant role in clinical oncology. In one study, 80% of patients with cancer at a major academic center admitted to employing CAM, with 60% using vitamins (including mega-dose preparations) and 38% using a variety of herbal supplements.1 This is a startling percentage, particularly because one might expect under-reporting by patients inclined to hide this information from their physicians. A similar proportion of patients in phase I clinical trials use CAM in parallel with study drugs.18 Although the patients presented in our report are Asian, CAM use is by no means restricted to that population. It is also noteworthy that the TCM arsenic trioxide, historically a frequent component of CAM, has been incorporated into the treatment paradigm for acute leukemia.19,20
Although the three patients presented here took a variety of CAM agents, all used Ling Zhi, also known as Reishi, prepared from the edible mushroom Ganoderma lucidum (G. lucidum). G. lucidum has been shown to have anticancer activity in vitro and in mouse models of cancer.21 A number of antineoplastic activities have been described for G. lucidum, including nuclear factor κB and protein kinase C inhibition, immune modulation, and direct cytotoxicity.22–24 An epiphenomenon of reduced AFP production without direct antitumor effect is also possible, noting the history of patient 1. These cases underscore the need for oncologists to be aware of CAM agents such as Ling Zhi, not only because they may be active against HCC, but also because concurrent use of these agents with chemotherapy, as in our first patient, might confound the attribution of results in clinical trials.
There are other case reports and a small case series of G. lucidum use in patients with various cancers.25–27 The next step should be to systematically study G. lucidum in patients with cancer. We are attempting to do just that at UCSF and the National Cancer Centre Singapore, but we have been hampered by an inability to find standardized supplies of Ling Zhi prepared according to current good manufacturing practices. We hope that a study will begin in 2011.
The author(s) indicated no potential conflicts of interest.
|1.||MA Richardson, T Sanders, JL Palmer, etal: Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology J Clin Oncol 18: 2505– 2514,2000 Link, Google Scholar|
|2.||FJ Hlubocky, MJ Ratain, M Wen, etal: Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: A study of prognosis, quality of life, and preferences for decision making J Clin Oncol 25: 548– 554,2007 Link, Google Scholar|
|3.||S Oquiñena, F Guillen-Grima, M Iñarrairaegui, etal: Spontaneous regression of hepatocellular carcinoma: A systematic review Eur J Gastroenterol Hepatol 21: 254– 257,2009 Crossref, Medline, Google Scholar|
|4.||TJ Lin, LY Liao, CL Lin, etal: Spontaneous regression of hepatocellular carcinoma: A case report and literature review Hepatogastroenterology 51: 579– 582,2004 Medline, Google Scholar|
|5.||H Kojima, N Tanigawa, S Kariya, etal: A case of spontaneous regression of hepatocellular carcinoma with multiple lung metastases Radiat Med 24: 139– 142,2006 Crossref, Medline, Google Scholar|
|6.||S Kondo, T Okusaka, H Ueno, etal: Spontaneous regression of hepatocellular carcinoma Int J Clin Oncol 11: 407– 411,2006 Crossref, Medline, Google Scholar|
|7.||P Wu, JJ Dugoua, O Eyawo, etal: Traditional Chinese medicines in the treatment of hepatocellular cancers: A systematic review and meta-analysis J Exp Clin Cancer Res 28: 112,2009 Crossref, Medline, Google Scholar|
|8.||DM Parkin, F Bray, J Ferlay, etal: Estimating the world cancer burden: Globocan 2000 Int J Cancer 94: 153– 156,2001 Crossref, Medline, Google Scholar|
|9.||HY Yoo, CH Patt, JF Geschwind, etal: The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time J Clin Oncol 21: 4329– 4335,2003 Link, Google Scholar|
|10.||CL Lai, PC Wu, GC Chan, etal: Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma: A prospective randomized trial Cancer 62: 479– 483,1988 Crossref, Medline, Google Scholar|
|11.||W Yeo, KC Lam, B Zee, etal: Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy Ann Oncol 15: 1661– 1666,2004 Crossref, Medline, Google Scholar|
|12.||JM Llovet, S Ricci, V Mazzaferro, etal: Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359: 378– 390,2008 Crossref, Medline, Google Scholar|
|13.||AL Cheng, YK Kang, Z Chen, etal: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10: 25– 34,2009 Crossref, Medline, Google Scholar|
|14.||M Pinter, W Sieghart, I Graziadei, etal: Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis Oncologist 14: 70– 76,2009 Crossref, Medline, Google Scholar|
|15.||MA Wörns, A Weinmann, K Pfingst, etal: Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis J Clin Gastroenterol 43: 489– 495,2009 Crossref, Medline, Google Scholar|
|16.||P Chow, TC Kiat, TB Choo, etal: Tamoxifen in hepatocellular carcinoma Lancet 352: 819– 820,1998 Crossref, Medline, Google Scholar|
|17.||AA Miller, DJ Murry, K Owzar, etal: Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301 J Clin Oncol 27: 1800– 1805,2009 Link, Google Scholar|
|18.||GK Dy, L Bekele, LJ Hanson, etal: Complementary and alternative medicine use by patients enrolled onto phase I clinical trials J Clin Oncol 22: 4810– 4815,2004 Link, Google Scholar|
|19.||SL Soignet, P Maslak, ZG Wang, etal: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide N Engl J Med 339: 1341– 1348,1998 Crossref, Medline, Google Scholar|
|20.||S Waxman, KC Anderson: History of the development of arsenic derivatives in cancer therapy Oncologist 6: 3– 10,2001 suppl 2 Crossref, Medline, Google Scholar|
|21.||D Sliva: Ganoderma lucidum (Reishi) in cancer treatment Integr Cancer Ther 2: 358– 364,2003 Crossref, Medline, Google Scholar|
|22.||BS Min, JJ Gao, N Nakamura, etal: Triterpenes from the spores of Ganoderma lucidum and their cytotoxicity against meth-A and LLC tumor cells Chem Pharm Bull (Tokyo) 48: 1026– 1033,2000 Crossref, Medline, Google Scholar|
|23.||SB Lin, CH Li, SS Lee, etal: Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest Life Sci 72: 2381– 2390,2003 Crossref, Medline, Google Scholar|
|24.||D Sliva, C Labarrere, V Slivova, etal: Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells Biochem Biophys Res Commun 298: 603– 612,2002 Crossref, Medline, Google Scholar|
|25.||S Oka, S Tanaka, S Yoshida, etal: A water-soluble extract from culture medium of Ganoderma lucidum mycelia suppresses the development of colorectal adenomas Hiroshima J Med Sci 59: 1– 6,2010 Medline, Google Scholar|
|26.||W Cheuk, JK Chan, G Nuovo, etal: Regression of gastric large B-cell lymphoma accompanied by a florid lymphoma-like T-cell reaction: Immunomodulatory effect of Ganoderma lucidum (Lingzhi)? Int J Surg Pathol 15: 180– 186,2007 Crossref, Medline, Google Scholar|
|27.||MA Ghafar, E Golliday, J Bingham, etal: Regression of prostate cancer following administration of Genistein Combined Polysaccharide (GCP), a nutritional supplement: A case report J Altern Complement Med 8: 493– 497,2002 Crossref, Medline, Google Scholar|
This report was prepared with approval from the University of California at San Francisco Committee on Human Research and in accordance with the rules on human research at the National Cancer Centre Singapore. Institutional review board approval was not required because the study was retrospective and noninterventional and required no patient contact.